Literature DB >> 2655661

Prorenin and renin as separate mediators of tissue and circulating systems.

J E Sealey1, S Rubattu.   

Abstract

The renin gene is expressed in extrarenal tissues. High concentrations of renin occur in female reproductive organs: the adrenals of rats and mice have intermediate levels. The testis also synthesizes renin, as does the anterior pituitary. In contrast, very low levels of renin (ie, below plasma levels) are found in the heart and extrarenal vascular tissues. The predominant form of renin in the human ovary, placenta, and uterus is prorenin and the human ovary, testis, and adrenals have been shown to secrete prorenin into the circulation. The kidney is the only organ that secretes active renin and it is also the major source of plasma prorenin. We have used the ovary as a model to study extrarenal renin. Ovarian prorenin secretion changes dynamically during the menstrual cycle and during gestation. Secretion occurs during the LH surge and when hCG is present in the blood during pregnancy. Plasma active renin does not change concurrently and only low levels of active renin are found in association with very high concentrations of prorenin in ovarian follicular fluid after gonadotropin stimulation. To explain the preponderance of prorenin, and the virtual absence of renin in the ovary we hypothesize that prorenin need not be converted to active renin to have effect. In vitro, when prorenin is acidified to pH 3.3 or cooled to 0 degrees C, it develops intrinsic catalytic activity without cleavage of the prosegment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655661     DOI: 10.1093/ajh/2.5.358

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

1.  Prorenin in ovarian cyst fluid.

Authors:  C M Bessant; P A Charlton; M J Price-Jones; J Kay; W A Reid
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

2.  High plasma prorenin in non diabetic siblings of non insulin-dependent diabetes mellitus patients.

Authors:  N Glorioso; C Troffa; G Tonolo; F Filigheddu; F Dettori; M Ciccarese; A Saller; A Soro; E Brocco; P Pinna-Parpaglia; F Mantero; P P Faronato; R Nosadini; M Maioli
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

3.  Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.

Authors:  M Véniant; J Ménard; P Bruneval; S Morley; M F Gonzales; J Mullins
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

Review 4.  Biochemistry and pharmacology of the renin-angiotensin system.

Authors:  C I Johnston
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  A genetically clamped renin transgene for the induction of hypertension.

Authors:  Kathleen M I Caron; Leighton R James; Hyung-Suk Kim; Scott G Morham; Maria Luisa S Sequeira Lopez; R Ariel Gomez; Timothy L Reudelhuber; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 6.  The cardiac renin-angiotensin system: physiological relevance and pharmacological modulation.

Authors:  J Holtz
Journal:  Clin Investig       Date:  1993

7.  Cosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure.

Authors:  T W Kurtz; L Simonet; P M Kabra; S Wolfe; L Chan; B L Hjelle
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

Review 8.  The molecular biology of human renin and its gene.

Authors:  J D Baxter; M N James; W N Chu; K Duncan; M A Haidar; C T Carilli; T L Reudelhuber
Journal:  Yale J Biol Med       Date:  1989 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.